Financials data is unavailable for this security.
View more
Year on year Bafna Pharmaceuticals Ltd 's net income fell -35.19% from 113.38m to 73.48m despite revenues that grew 32.15% from 1.15bn to 1.53bn. An increase in the selling, general and administrative costs as a percentage of sales from 13.74% to 18.33% was a component in the falling net income despite rising revenues.
| Gross margin | 26.69% |
|---|---|
| Net profit margin | 0.19% |
| Operating margin | 0.32% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Bafna Pharmaceuticals Ltd fell by 64.14m. However, the company earned 94.85m from its operations for a Cash Flow Margin of 6.22%. In addition the company used 150.54m on investing activities and also paid 8.45m in financing cash flows.
| Cash flow per share | 2.33 |
|---|---|
| Price/Cash flow per share | 33.15 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
